KRAS and cancer: CodeBreaK 101 (NCT04185883) is an ongoing phase 1 trial exploring sotorasib monotherapy and in combination with other anti-cancer therapies, including anti-EGFR agents (panitumumab), MEK inhibitors, and ICIs, in advanced solid tumors harboring the KRAS G12C mutation.